1. Kang SY, Lee SB, Kim YS, Kim Z, Kim HY, Kim HJ, et al. Breast cancer statistics in Korea, 2018. J Breast Cancer. 2021; 24:123–137. PMID:
33913273.
2. Long Q, Wang Y, Che G. Primary lung cancer after treatment for breast cancer. Int J Womens Health. 2021; 13:1217–1225. PMID:
34908880.
3. Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC Cancer. 2011; 11:260. PMID:
21693006.
4. Jung HK, Park S, Kim NW, Lee JE, Kim Z, Han SW, et al. Development of second primary cancer in Korean breast cancer survivors. Ann Surg Treat Res. 2017; 93:287–292. PMID:
29250506.
5. Emons G, Mustea A, Tempfer C. Tamoxifen and endometrial cancer: a Janus-headed drug. Cancers (Basel). 2020; 12:2535. PMID:
32906618.
7. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24:3726–3734. PMID:
16720680.
8. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021; 385:2336–2347. PMID:
34914339.
9. Jabagi MJ, Vey N, Goncalves A, Le Tri T, Zureik M, Dray-Spira R. Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France. JAMA Netw Open. 2019; 2:e187147. PMID:
30657534.
10. Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJ, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 2019; 5:318–325. PMID:
30570657.
11. Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007; 12:253–270. PMID:
17405890.
12. Kaplan HG, Calip GS, Malmgren JA. Maximizing breast cancer therapy with awareness of potential treatment-related blood disorders. Oncologist. 2020; 25:391–397. PMID:
32073195.
13. Piccart M, van't Veer LJ, Poncet C, Lopes Cardozo JM, Delaloge S, Pierga JY, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021; 22:476–488. PMID:
33721561.
14. Villarreal-Garza C, Ferrigno AS, De la Garza-Ramos C, Barragan-Carrillo R, Lambertini M, Azim HA Jr. Clinical utility of genomic signatures in young breast cancer patients: a systematic review. NPJ Breast Cancer. 2020; 6:46. PMID:
33062888.